This study investigated the prevalence, risk factors and rate of recognition of anxiety and depression in 50 patients hospitalized for exacerbation of chronic obstructive pulmonary disease (COPD). Using the Primary Care Evaluation of Mental Disorders questionnaire, 13 patients were identified as having depression, four had anxiety and eight had a combination of the two. Patients with anxiety and/or depression had a significantly higher partial pressure of oxygen and pH, and a lower partial pressure of carbon dioxide, in arterial blood on admission, more severe dyspnoea after a 6-min walk test and less improvement of dyspnoea from admission to discharge than COPD patients without anxiety and/or depression. Two patients were referred to a mental health specialist during their hospitalization, indicating a low rate of recognition. The results suggest that patients with mental disorders are referred and admitted to hospital earlier in the course of a COPD exacerbation due to earlier and more intense perception of dyspnoea.
Introduction
Chronic obstructive pulmonary disease (COPD) is a major cause of chronic morbidity and mortality throughout the world and it is the fourth leading cause of death worldwide. 1 COPD and major depression are among the diseases associated with the greatest loss of disabilityadjusted life years (DALY). 2 In 1990, major depression was in fourth place and COPD was in 12th place. Projections to the year 2020 show that their burden will continue to rise, putting major depression in second place and COPD in fourth place.
Patients with COPD frequently find themselves in a vicious cycle of dyspnoea, deteriorating exercise performance, restricted mobility and social isolation. Anxiety and/or depression are also important parts of that cycle. 3 -7 Several authors have found increased levels of anxiety and/or depression in patients with COPD, 4 -6,8 -18 whereas others have not. 7, 19, 20 These two mental health disorders also influence patients' quality of life; 7,10 the mental disorders themselves can be further J Regvat, A Žmitek, M Vegnuti et al.
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aggravated by patients' disabilities and, in turn, they can exaggerate patients' COPD symptoms. When recognized, they are, however, treatable and should be treated since health is regarded as a state of complete physical, social and mental wellbeing. In all aspects, a healthy population is an indispensable prerequisite of a flourishing and wealthy society. 21 Investigating anxiety and depression in COPD patients is challenging because of the subjective nature of the diagnostic process, the variability in presentation and the significant overlap of symptoms between COPD, anxiety and depression (i.e. dyspnoea, choking, chest tightness, palpitations, tremor, fatigue, disordered sleep and loss of appetite). 15, 18, 22 The aim of the present study was to assess the prevalence of anxiety and depression in patients successively admitted to hospital for a COPD exacerbation. The secondary objectives were to evaluate the possible differences between patients with and without anxiety and/or depression, and to find out how often these disorders are recognized in a hospital setting and appropriately managed.
Patients and methods

PATIENTS
The study included successive patients with a COPD exacerbation (the only inclusion criterion) who presented at the Department of Pulmonary Diseases, University Clinical Centre Maribor, Maribor, Slovenia between 1 June and 31 August 2005. Patients included in the study had to: (i) provide signed written consent; (ii) be able to understand the questions in the questionnaire; and (iii) be capable of having a sensible conversation with the interviewer. If they were unable to do so, they were excluded from the study. COPD was defined according to the American Thoracic Society/European Respiratory Society (ATS/ERS) criteria as a ratio of forced expiratory volume in 1 s to vital capacity (FEV 1 /FVC) before and after inhalation of 400 µg salbutamol of < 0.7 and reversibility in FEV 1 of < 12% of predicted FEV 1 .
3
This study was approved by the National Medical Ethics Committee of the Republic of Slovenia, Ljubljana, Slovenia.
MEASUREMENT OF ANXIETY AND DEPRESSION
The Primary Care Evaluation of Mental Disorders (PRIME-MD) questionnaire was used to assess the presence of mental disorders. 23 In its full original form it assesses five groups of mental disorders: anxiety, mood disorders, somatoform disorders, alcohol abuse and eating disorders. It was decided, however, to investigate only the most common two: anxiety (panic disorder, generalized anxiety disorder and anxiety disorder not otherwise specified) and mood disorders (minor depression, major depression, major depression in remission and dysthymia). PRIME-MD is designed as a two-step assessment and comprises a patient questionnaire and a structured clinical interview. 23 The patient questionnaire is intended as a screening tool. Patients report their symptoms from the five groups of mental disorders on a preprepared sheet. If they experience a notable number of symptoms, the structured interview is undertaken. In the present study the patient questionnaire was omitted. It is designed as an algorithm, which guides the interviewer toward the correct diagnosis. There was no need for patient screening since all the patients were intended to be interviewed with the structured clinical interview, guided by a doctor.
The interview was performed on the day J Regvat, A Žmitek, M Vegnuti et al. High prevalence of anxiety and depression in COPD of discharge from hospital to avoid any bias from the poor health perception, poor general condition and worse dyspnoea that the patient experienced during the exacerbation. The sensitivity of the questionnaire for mood disorders and anxiety disorders is 67% and 69%, respectively; the specificity for mood disorders and anxiety disorders is 92% and 90%, respectively; and the accuracy for mood disorders and anxiety disorders is 84% and 86%, respectively. 23 PRIME-MD was designed for use in primary care, 23 but is equally useful in a hospital setting. 27 and reported the level of dyspnoea before (this value was also used as the discharge dyspnoea value) and after the test. Information on the following variables was obtained by questionnaire: age, sex, number of comorbid chronic diseases, smoking status, number of exacerbations in the last year that required hospitalization and a history of prior anxiety and/or depression. When patients had been prescribed treatment or had been referred to a mental health specialist during their hospital stay, or the observation of the patient's changed mental status had been mentioned in their discharge letter (i.e. all before the interview on the day of discharge), it was acknowledged as a recognized case of anxiety and/or depression (by the treating physician).
15
OTHER RESEARCH VARIABLES
STATISTICAL ANALYSES
As a null hypothesis it was assumed that anxiety and/or depression are often present in COPD patients, yet they remain mostly unrecognized and untreated. Furthermore, it was anticipated that patients with anxiety and/or depression are older, more often women, heavy and/or active smokers, with more comorbidities, more severe COPD, more frequent hospital admissions and a history of mental disorder in the past. Worse dyspnoea, blood gas analysis and shorter distance achieved in the 6-min walk test were also assumed as a null hypothesis to be linked to anxiety and/or depression.
Statistical analyses were carried out using the SPSS ® statistical package, version 8.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . Descriptive statistics for data analysis were used: frequencies, mean and distribution, and mean ± SD were calculated unless stated J Regvat, A Žmitek, M Vegnuti et al.
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otherwise. For testing the null hypothesis, Kruskal-Wallis and χ 2 -tests were used for nonparametric and nominal variables, respectively. For statistical analysis of data, patients with anxiety, depression and a combination of the two were placed in one group. This decision was made primarily for methodological reasons: (i) the individual groups of patients with the specified disorders were quite small and unevenly distributed; (ii) when the individual groups of patients with anxiety, depression or the combined disorder were compared there was no statistically significant difference between them; (iii) anxiety and depression often appear together (in the present study, this occurred in one-third of patients); and (iv) treatment of both disorders is similar (antidepressants). By grouping the patients this way, two groups of even size (with and without anxiety and/or depression) were compared. Statistical analyses of these two groups of patients were carried out using the χ 2 -test and Mann-Whitney U test. A P-value < 0.05 was considered to be statistically significant.
Results
In the 3-month period of the study, 55 patients were hospitalized because of COPD exacerbation. Three were excluded from the study because of lack of an understanding of the language, one because of mental retardation and one failed to give their written consent. A total of 50 patients with COPD exacerbation therefore participated in the study (35 males, 15 females). Their mean ± SD age was 72.4 ± 8.4 years and FEV 1 was 1.1 ± 0.4 l/s; FEV 1 was 46.9 ± 17.6% of that predicted.
The characteristics of patients with and without anxiety and/or depression are shown in Table 1 . A total of 25 patients (50%) had anxiety and/or depression: 13 (26%) only had depression, four (8%) had anxiety and eight (16%) had both mental disorders. Three (6%) patients were experiencing major depression and two (4%) were experiencing panic attacks. There were no significant differences between the two groups regarding sex, age, smoking status, comorbidities, 6-min walking distance, COPD severity (i.e. FEV 1 as a percentage of predicted) and number of hospitalizations for COPD exacerbations in the year before the study. Anxiety and depression were more often found in patients with a history of prior treated anxiety and/or depression (P = 0.021). Before the introduction of the questionnaire, none of the patients had been prescribed treatment for anxiety and/or depression by a treating physician (without consultation with a mental health specialist), and neither was the change in mental status registered in the medical chart or the discharge letter. During their hospital stay, two patients (8% of all patients diagnosed with anxiety and/or depression) were referred to a mental health specialist and received treatment. Among all patients, two with major depression and two with panic attacks would have been overlooked if the study and the PRIME-MD interview had not been performed.
Patients with anxiety and/or depression experienced significantly worse dyspnoea after the 6-min walk test (P = 0.01) and a significantly smaller improvement of dyspnoea from admission to hospital discharge (P = 0.046). Comparison between the two groups regarding dyspnoea at discharge and worsening of dyspnoea from beginning to end of the 6-min walk test did not reach statistical significance.
There was a significant correlation between dypsnoea and a decline in lung function (FEV 1 as a percentage of predicted): J Regvat, A Žmitek, M Vegnuti et al. 
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Pearson's correlation, P = 0.008 for dyspnoea at discharge and P = 0.034 for dyspnoea after the 6-min walk test. In contrast, lung function alone (FEV 1 as a percentage of predicted) did not reach statistical significance for predicting anxiety and/or depression.
In terms of blood gas analysis on admission, patients with COPD and anxiety and/or depression had significantly higher partial pressure of oxygen (P = 0.002), lower partial pressure of carbon dioxide (P = 0.047) and higher pH than patients without anxiety and/or depression (P = 0.042).
The comorbid diseases experienced by the patients were arterial hypertension (21), heart failure (7), ischaemic heart disease (3), cancer ( 
Discussion
The hospitalized COPD patient population in the present study showed a prevalence of anxiety and/or depression of 50%. The results are difficult to compare with other published studies because they have included very different groups of patients. 12 The tools for assessing mental disorders have also differed widely between studies (i.e. different self-reported questionnaires, guided interviews with a nurse or a doctor not specialized in psychiatric medicine, discussion with a mental health specialist). 28 Nevertheless, three studies have been identified with comparable groups of patients (admitted to hospital because of an exacerbation) and these show comparable results. 4, 8, 9 Several authors have linked anxiety and depression with the perception of dyspnoea. 4,5,10 There were no differences 
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between the two groups in terms of the level of dyspnoea on admission to hospital in the present study. The patients with anxiety and/or depression did, however, show less improvement in their dyspnoea from admission until discharge, indicating that dyspnoea perception between exacerbations (i.e. in the stable state) might be influenced by the patient's mental health status. Patients with anxiety and/or depression also reported significantly worse dyspnoea after the 6-min walk test. There was, however, no correlation between exercise performance and mental health, or between exercise performance and dyspnoea. Thus, there seems to be a direct connection between the perception of dyspnoea and anxiety and depression.
There was a significant correlation between dyspnoea and decline in lung function (FEV 1 as a percentage of predicted) for dyspnoea at discharge and for dyspnoea after the 6-min walk test. In contrast, lung function alone (FEV 1 as a percentage of predicted) did not reach statistical significance for predicting anxiety and/or depression. It should be noted, that the group of patients with mild COPD was very small (two patients), which was not an unexpected finding as these patients rarely need hospitalization because of an exacerbation. Thus, had the present study included a greater number of patients with mild COPD, the findings might have shown a statistically significant difference. The lack of a statistically significant difference and the high prevalence of anxiety and depression observed suggests that mental disorders are also common in patients with milder COPD. A few studies have reported that lung function is a predictor of mental health, 12,13 but others have not confirmed this finding. 8, 10, 11, 14 An interesting finding was the association between anxiety and/or depression and blood gas analysis, where patients with mental disorders had higher partial pressure of oxygen, lower partial pressure of carbon dioxide and higher pH on admission than those without mental disorders. This suggests that patients with anxiety and/or depression are referred and admitted to hospital earlier in the course of an exacerbation. No related articles were identified through a literature search, although the data reported here could be explained by the results of previously published studies of panic attacks. 29, 30 These studies have reported that there could be a hypersensitive carbon dioxide receptor in the respiratory centre that is involved in triggering panic attacks by carbon dioxide inhalation and by infusion of lactate. Patients with such hypersensitivity sense an exacerbation earlier, this triggers dyspnoea, they hyperventilate more, dyspnoea worsens and a vicious cycle ensues. Another study has discussed the high prevalence of depression in COPD patients attending a hospital outpatient clinic and implied that referral from a general practitioner could have been the result of depression since depressed patients with COPD may have experienced only a subjective worsening of their disease. 7 It could be speculated that mental disorders play a protective role (fear is essentially a signal for danger) since patients appear to become aware of an exacerbation earlier. On the other hand, their responses are significantly exaggerated, possibly reflecting the coexistence of a mental disorder, and this can have a deleterious effect on quality of life.
A history of mental disorder is important in predicting patients who might become anxious and/or depressed during chronic illness. 13 This was confirmed in the present study, since patients with anxiety and/or J Regvat, A Žmitek, M Vegnuti et al.
depression were more likely to have a history of a prior treated mental disorder. Only two patients out of 25 with anxiety and/or depression were referred to a mental health specialist by the physician before the PRIME-MD diagnoses were established in the study. Among all patients, two with major depression and two with panic attacks would have been overlooked if the study and the PRIME-MD interview had not been performed. Unfortunately, these results are not very surprising as several authors have confirmed that mental disorders in patients with somatic diseases and complaints are often overlooked and that, even when anxiety and/or depression are confirmed, patients are rarely treated. 15, 16, 23 There were no differences between the two groups of patients in the present study regarding age, sex, number of comorbidities, smoking status and number of hospitalizations for COPD exacerbations in the year before the study was conducted.
The prevalence of major depression in older and younger people is similar, but additional clinically significant symptoms of depression are present in 8 -16% of elderly cases. 31 Since COPD is not a disease of young people and young patients with mild stages of the disease do not normally have many exacerbations that require hospitalization, the present study included mostly elderly patients. The age span was too small to detect any differences in the prevalence of anxiety and/or depression based on age. Besides this, the PRIME-MD questionnaire only identifies a developed disease (high specificity) and disregards individual symptoms (low sensitivity) if they do not reach a significant number that defines a disease (e.g. two or five out of nine symptoms for minor or major depression, respectively). Several other authors have also failed to show any difference in prevalence based on patient's age. 8,10 -12 Some authors have found that women with COPD more commonly have anxiety and/or depression, 8, 10, 13, 19 whilst others have failed to show this. 11, 12 No differences between the sexes were identified in the present study, but sex distribution was quite uneven (i.e. 35 males to 15 females). The number of comorbid diseases was recorded for each patient but, in contrast to a previous study, 32 this did not predict the occurrence of mental disorder. Existing scales for measuring the burden and impact of comorbid diseases were not, however, used in the present study.
In contrast to a previous study, 17 the number of hospitalizations for exacerbations of COPD did not differ significantly between the two groups. Only hospitalizations for exacerbations were counted in the present study and there was, therefore, no information on the patients' utilization of emergency rooms and general practitioners' offices.
Some authors have reported that anxiety and/or depression are more common in patients with COPD who smoke. 6, 8 Other studies have also emphasized a link between smoking and mental disorders. 33, 34 No differences regarding the number of packyears smoked and current smoking status were observed between the two groups of patients in the present study. It should be noted, however, that information on the current smoking status was based on the patients' responses in the questionnaire, so their answers could have been misleading. Breath carbon monoxide measurements were not performed. There were a number of limitations to the present study. As explained earlier, patients with anxiety, depression and a combination of the two disorders were analysed as one group, mainly for methodological reasons.
The present study included only hospitalized COPD patients and results can, therefore, only be interpreted in this context and it does not represent the whole population of COPD patients. The use of a fixed cut-off (i.e. a patient has or does not have a mental disorder) to distinguish patients with and without anxiety or depression can be questioned. The PRIME-MD questionnaire that was used has high specificity and, therefore, lacks some sensitivity since the individual symptoms of mental disorder, if not present in a significant number, are disregarded. On the other hand, it was easy to use and, because it was designed as a guided interview, the investigator could quite reliably distinguish a patient's COPD symptoms from those due to anxiety and/or depression with the use of extra questions and explanations. There was no control group in the present study, so it cannot be stated reliably that anxiety and/or depression are more frequent in hospitalized patients with COPD than in patients with other pulmonary or non-pulmonary diseases.
From the clinical point of view, the present study underlines the importance of being aware of the high prevalence of anxiety and depression in patients with COPD. These patients are referred to hospital earlier in the course of an exacerbation or perhaps even without objective worsening of their symptoms (i.e. without an exacerbation that needs special treatment). Sometimes they are probably unjustifiably hospitalized due to unexplainably worse than expected dyspnoea. Anxiety and depression can also have a strong impact on patients' quality of life, though analysis of this was not within the scope of the present study. As mental disorders often go unrecognized in patients with somatic disorders, the present study, being the first to investigate this topic in patients with COPD in Slovenia, is important as it identified that mental disorders also occur in this group of patients. This will, hopefully, result in better recognition and treatment by healthcare professionals.
In conclusion, the prevalence of anxiety and depression among patients hospitalized for exacerbation of COPD was high, but only a few were recognized and treated. There are no effective measures to halt the decline in lung function in COPD so the emphasis must be on improving symptoms and alleviating daily functioning. The mental state of the patient appears to be an important determinant of their perception of dyspnoea, and it also has a strong impact on their quality of life, and should be evaluated in every patient with COPD.
